Immunotherapy of melanoma.
Immunotherapy of melanoma.
复制标题
DOI：
10.5114/wo.2018.73889
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Rutkowski P
中科院分区：
文献类型：
--
作者：
Lugowska I;Teterycz P;Rutkowski P
免疫疗法目前正在改变肿瘤学的格局。如今，转移性或不可切除的黑色素瘤患者的标准治疗包括免疫调节方式，如抗PD-1药物（纳武单抗，派姆单抗）和抗CTLA-4抗体伊匹单抗。与这些治疗相关的无进展生存期和总生存期的改善是前所未有的，并已在III期试验中得到证实。在某些患者组中，通过组合两种类型的抗体，可以进一步提高免疫疗法在转移性环境中的疗效。最新的临床数据表明，免疫疗法治疗也有利于辅助治疗的患者。基于免疫应答的其他治疗方法（例如溶瘤病毒或过继细胞疗法）已被证明在特定临床情况下有用。黑色素瘤治疗的未来仍在发展，新的分子靶点正在发明，希望目前的努力将导致进一步改善患者的生存。本文就黑色素瘤的免疫治疗现状进行综述，并提出可能的发展方向。
The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of progression free survival and overall survival connected with those treatments were unprecedented and have been confirmed in stage III trials. The efficacy of immunotherapy in metastatic setting can be further upgraded in some groups of patients by combining both types of antibodies. Latest clinical data suggest that treatment with immunotherapy can be also favorable for patients in adjuvant setting. Other treatment approaches based on immunological response (e.g. oncolytic viruses or adoptive cell therapy) have been proven useful in specific clinical situations. The future of melanoma treatment is still evolving, new molecular targets are being invented and hopefully current endeavors will led to further improvement of patients’ survival. This review aims to summarize current state of immunotherapy in melanoma and identifying possible directions of development.